- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07636187
Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters (PROACTIVE)
A substantial portion of the United States population remains overdue for key screenings, despite availability and insurance coverage of preventive health services. Barriers for completion and remaining up to date with screening include patients not remaining actively engaged with their care team, time constraints during office visits, and operational strain. This project aims to implement and evaluate a primary care visit-based program that harmonizes multiple preventive health and chronic disease management care gaps, reduces staff burden, and improves ordering and subsequent patient follow through on completion of overdue care gaps.
In this study, the investigators will evaluate nudges to clinicians and patients to help increase screening completion for multiple care gaps identified as high priority by primary care, including imaging (Mammogram, DEXA) and labs (Diabetes Management (Hemoglobin A1C, Basic Metabolic Panel, and Urine Microalbumin), Hepatitis C, and Lipids). This will be a 6 month, stepped-wedge, pragmatic trial conducted at Penn Medicine.
Przegląd badań
Status
Warunki
Szczegółowy opis
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- University of Pennsylvania Health System
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
All patients must meet the following criteria to be eligible:
- 18 years or older
- A scheduled new or return (non-urgent/sick) primary care visit at one of the study practices
- Overdue for at least one of the included care gaps according to Health Maintenance: Mammogram, DEXA, Hemoglobin A1C, Basic Metabolic Panel, Urine Microalbumin, Lipids, Hepatitis C
- Last eligible office visit was greater than or equal to 3 months ago
Exclusion Criteria:
As this trial is integrated with routine clinical operations, there will be no exclusion criteria. However, for each care gap independently, we will exclude all patient visits throughout the remaining trial duration after the patient's first eligible office visit within the trial duration. In other words, each patient will contribute data from at most one eligible office visit.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Brak interwencji: Control Condition
During the control condition, clinics will receive standard of care.
|
|
|
Eksperymentalny: Active Intervention
During the active intervention, clinics will receive both clinician and patient facing nudges.
Patient nudges will be pre- and post-visit text message reminders about their overdue care gaps.
Clinician nudges will be default pended orders for overdue care gaps and an EHR Smart Data Element communication banner notifying the provider that a pre-visit reminder was sent to the patient and that orders have been pended for their review.
|
The patient nudges will be delivered by a series of one to three text messages.
Patients will receive the pre-visit text message 2 days prior to their scheduled primary care visit.
This message will remind them that they are overdue for their preventive care imaging and/or labs and encourage them to speak with their provider about screening completion during their upcoming appointment.
All patients who complete their primary care visit and whose provider signed at least one of their pended orders will be sent post-visit text messages 7 and 14 days after completion, if they have not yet scheduled or completed their overdue labs and/or imaging.
The messages delivered at 7 and 14 days will remind patients that appointments for lab and imaging are available for them and provide phone number(s) to call for scheduling and a link to complete scheduling online.
Patients will also have the option to engage with a bi-directional support menu via text message.
The default pended orders will be automatically placed into the patient's primary care visit encounter via a custom Epic extension for each included care gap (mammogram, DEXA, hemoglobin A1C, basic metabolic panel, urine microalbumin, lipids, and Hepatitis C) that the patient is overdue for according to their Health Maintenance status.
Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
An electronic health record (EHR) communication will be visible to the provider and entire care team during the visit encounter.
This smart data element (SDE) communication will display in the patient's EHR encounter as a section in pre-charting, check-in, and rooming, and will notify the clinician and care team that a pre-visit communication was sent to the patient regarding their overdue status for their preventive care imaging and/or labs.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Mammogram Screening Completion (3 months)
Ramy czasowe: Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete a mammogram within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
|
Hepatitis C Screening Completion (3 months)
Ramy czasowe: Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete Hepatitis C screening within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
|
Lipids Screening Completion (3 months)
Ramy czasowe: Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete lipids screening within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
DEXA Screening Completion (3 months)
Ramy czasowe: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete DEXA screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Hemoglobin A1C Screening Completion (3 months)
Ramy czasowe: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hemoglobin A1C screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Basic Metabolic Panel Screening Completion (3 months)
Ramy czasowe: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Basic Metabolic Panel screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Urine Microalbumin Screening Completion (3 months)
Ramy czasowe: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Urine Microalbumin screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Mammogram Screening Completion (6 months)
Ramy czasowe: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete a mammogram within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Hepatitis C Screening Completion (6 months)
Ramy czasowe: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hepatitis C screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Lipids Screening Completion (6 months)
Ramy czasowe: Within 6 months after the first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete lipids screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
DEXA Screening Completion (6 months)
Ramy czasowe: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete DEXA screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Hemoglobin A1C Screening Completion (6 months)
Ramy czasowe: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hemoglobin A1C screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Basic Metabolic Panel Screening Completion (6 months)
Ramy czasowe: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Basic Metabolic Panel screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Urine Microalbumin Screening Completion (6 months)
Ramy czasowe: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Urine Microalbumin screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Shivan Mehta, University of Pennsylvania
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 859571
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .